RAFA: AI 评分 44/100 — AI 分析 (4月 2026)

Rafarma Pharmaceuticals, Inc. is a pharmaceutical company focused on the production and sale of generic antibiotics and specialty pharmaceuticals in Russia. The company operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Rafarma Pharmaceuticals, Inc. produces and distributes generic antibiotics and specialty pharmaceuticals in Russia, including cephalosporin-based and anti-cancer drugs. Operating as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd., it navigates the competitive landscape of the Russian pharmaceutical market with a focus on various drug formulations.

RAFA是做什么的？

Rafarma Pharmaceuticals, Inc., originally named Johnston Acquisition Corp. before its renaming in October 2012, is a multi-product pharmaceutical company specializing in the production and sale of drugs, generic antibiotics, and specialty pharmaceuticals within the Russian market. The company's product portfolio includes cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs, available in various forms such as injections, ampulla packaged products, child suspensions, tablets, and capsules. Additionally, Rafarma offers medications for accidental wounds, inflammatory eye diseases, and immunological disorders. Based in Sandy, Utah, Rafarma maintains a manufacturing and distribution facility in Russia, allowing it to serve the local market effectively. A significant collaboration with PlantEXT Ltd. is underway to research and manufacture medical cannabis suppositories targeting patients with inflammatory bowel disease, showcasing the company's innovation efforts. Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd. since October 19, 2020. The company focuses on providing a range of pharmaceutical products to address various medical needs in the Russian healthcare sector.

RAFA的投资论点是什么？

Rafarma Pharmaceuticals, Inc. presents a focused investment opportunity within the Russian pharmaceutical market, specializing in generic antibiotics and specialty drugs. With a market capitalization of $0.01 billion and a P/E ratio of 19.50, the company demonstrates potential for growth, supported by a gross margin of 7.3% and a profit margin of 3.2%. Key growth catalysts include the collaboration with PlantEXT Ltd. to develop medical cannabis suppositories and the expansion of its product offerings in the Russian market. However, the may be worth researching risks associated with operating in the OTC market and the competitive pressures within the pharmaceutical industry. The company's beta of 0.54 suggests lower volatility compared to the market.

RAFA在哪个行业运营？

Rafarma Pharmaceuticals, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, which is characterized by intense competition and regulatory scrutiny. The Russian pharmaceutical market, where Rafarma primarily operates, is influenced by government policies, pricing regulations, and local demand for affordable medications. The company's focus on generic antibiotics and specialty drugs positions it to capitalize on the growing demand for cost-effective healthcare solutions. However, it faces competition from both domestic and international players, including BIOE, IGPK, LMLLF, LVVV, and NRPR, requiring continuous innovation and strategic partnerships to maintain market share.

Drug Manufacturers - Specialty & Generic

Healthcare

RAFA有哪些增长机遇？

Expansion of Product Portfolio: Rafarma can expand its product portfolio by introducing new generic drugs and specialty pharmaceuticals to address unmet medical needs in the Russian market. This includes investing in research and development to create innovative formulations and dosages. The market for generic drugs is expected to grow as patents for branded drugs expire, providing a significant opportunity for Rafarma to increase its revenue and market share. Timeline: Ongoing.
Collaboration with PlantEXT Ltd.: The collaboration with PlantEXT Ltd. to research and manufacture medical cannabis suppositories for patients suffering from inflammatory bowel disease presents a unique growth opportunity. The market for medical cannabis is expanding globally, and Rafarma can leverage this partnership to enter a new and potentially lucrative market segment. Successful development and commercialization of these suppositories could significantly boost the company's revenue and brand recognition. Timeline: Ongoing.
Geographic Expansion within Russia: Rafarma can expand its geographic reach within Russia by establishing new distribution channels and partnerships with local pharmacies and healthcare providers. This will allow the company to reach a wider customer base and increase its sales volume. The Russian pharmaceutical market is vast and diverse, with significant regional variations in demand and healthcare infrastructure. Timeline: Ongoing.
Strategic Acquisitions and Partnerships: Rafarma can pursue strategic acquisitions and partnerships with other pharmaceutical companies to expand its product portfolio, access new technologies, and enter new markets. This includes acquiring companies with complementary product lines or technologies, as well as forming partnerships with research institutions and universities to develop new drugs and therapies. Timeline: Ongoing.
Focus on Export Markets: Rafarma can explore opportunities to export its products to other countries in the region, particularly those with similar healthcare needs and regulatory environments. This will allow the company to diversify its revenue streams and reduce its reliance on the Russian market. The export market for generic drugs is growing rapidly, driven by increasing demand for affordable healthcare solutions in developing countries. Timeline: 2027-2028.

Market capitalization of $0.01 billion indicates a micro-cap company with potential for high growth but also higher risk.
P/E ratio of 19.50 suggests the company is trading at a moderate valuation compared to its earnings.
Gross margin of 7.3% reflects the company's profitability after accounting for the cost of goods sold.
Profit margin of 3.2% indicates the percentage of revenue that turns into profit after all expenses, including taxes, are paid.
Beta of 0.54 suggests the stock is less volatile than the overall market.

RAFA提供哪些产品和服务？

Produces and sells generic antibiotics in Russia.
Offers specialty pharmaceuticals for various medical conditions.
Manufactures cephalosporin-based products.
Develops anti-cancer drugs in different formulations.
Provides drugs for accidental wounds and inflammatory eye diseases.
Researches and manufactures medical cannabis suppositories through a collaboration with PlantEXT Ltd.

RAFA如何赚钱？

Develops and manufactures generic and specialty pharmaceutical products.
Sells products through distribution channels in Russia.
Generates revenue from the sale of pharmaceutical products.
Collaborates with other companies for research and development.

Hospitals and clinics in Russia.
Pharmacies and drugstores.
Patients requiring generic antibiotics and specialty pharmaceuticals.
Healthcare providers prescribing medications.

Established manufacturing and distribution facility in Russia.
Collaboration with PlantEXT Ltd. for medical cannabis suppositories.
Focus on generic antibiotics and specialty pharmaceuticals.
Product portfolio addressing various medical needs.

什么因素可能推动RAFA股价上涨？

Ongoing: Expansion of product portfolio with new generic drugs and specialty pharmaceuticals.
Ongoing: Collaboration with PlantEXT Ltd. to develop and commercialize medical cannabis suppositories.
Ongoing: Geographic expansion within Russia to reach a wider customer base.
Upcoming: Potential strategic acquisitions and partnerships to expand market presence (Timeline: 2027).
Upcoming: Exploration of export opportunities to diversify revenue streams (Timeline: 2027-2028).

RAFA的主要风险是什么？

Ongoing: Intense competition from domestic and international pharmaceutical companies.
Potential: Regulatory changes in the Russian pharmaceutical market affecting pricing and market access.
Potential: Economic instability in Russia impacting demand for pharmaceutical products.
Potential: Fluctuations in currency exchange rates affecting profitability.
Ongoing: Risks associated with operating on the OTC Other tier, including limited liquidity and transparency.

RAFA的核心优势是什么？

Established manufacturing facility in Russia.
Focus on generic antibiotics and specialty pharmaceuticals.
Collaboration with PlantEXT Ltd. for innovative products.
Diverse product portfolio addressing various medical needs.

RAFA的劣势是什么？

Small market capitalization.
Low gross and profit margins.
Reliance on the Russian market.
OTC market listing.

RAFA有哪些机遇？

Expansion of product portfolio with new generic drugs.
Geographic expansion within Russia.
Strategic acquisitions and partnerships.
Growth in the medical cannabis market.

RAFA面临哪些威胁？

Intense competition from domestic and international players.
Regulatory changes in the Russian pharmaceutical market.
Economic instability in Russia.
Fluctuations in currency exchange rates.

RAFA的竞争对手是谁？

BIO-key International, Inc. — Operates in the security and identity access management sector, not directly comparable in pharmaceuticals. — (BIOE)
iG приобретете пакета акций — Unknown business description. — (IGPK)
LML Payment Systems Inc. — Operates in the payment processing sector, not directly comparable in pharmaceuticals. — (LMLLF)
Live Ventures Incorporated — A diversified holding company with operations in various industries, not directly comparable in pharmaceuticals. — (LVVV)
Newpark Resources, Inc. — Provides products and services to the oil and gas industry, not directly comparable in pharmaceuticals. — (NRPR)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Sergey Brusnitsin
Headquarters: Sandy, US
Founded: 2012

AI Insight

AI analysis pending for RAFA

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Rafarma Pharmaceuticals, Inc. do?

Rafarma Pharmaceuticals, Inc. is a pharmaceutical company that develops, manufactures, and sells generic antibiotics and specialty pharmaceuticals in Russia. The company's product portfolio includes cephalosporin-based products, anti-cancer drugs, and medications for various medical conditions. Rafarma operates a manufacturing and distribution facility in Russia and collaborates with PlantEXT Ltd. to research and manufacture medical cannabis suppositories. The company focuses on providing affordable and accessible healthcare solutions to the Russian market.

What do analysts say about RAFA stock?

As of 2026-03-17, there is no available analyst coverage for Rafarma Pharmaceuticals, Inc. due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks. Key valuation metrics include a P/E ratio of 19.50, a gross margin of 7.3%, and a profit margin of 3.2%. Growth considerations include the company's expansion plans, collaboration with PlantEXT Ltd., and potential strategic acquisitions.

What are the main risks for RAFA?

The main risks for Rafarma Pharmaceuticals, Inc. include intense competition from domestic and international pharmaceutical companies, regulatory changes in the Russian pharmaceutical market, economic instability in Russia, and fluctuations in currency exchange rates. Additionally, the company faces risks associated with operating on the OTC Other tier, including limited liquidity, transparency, and regulatory oversight. Investors should carefully consider these risks before investing in RAFA.